kedrab.com
Open in
urlscan Pro
151.101.66.159
Public Scan
Submitted URL: http://share.msgapp.com/jc.aspx?d=CWGMWDUCGAKEJ77FNZFUQW4RI4JRFDJO2RQFJ4F5KOU2Q2LNUCBIV4O7XWXM4ZGOMQ7HAAWBEPFHZZWAVEDBCB...
Effective URL: https://kedrab.com/ma-kedrab-benefits/
Submission: On November 15 via api from US — Scanned from DE
Effective URL: https://kedrab.com/ma-kedrab-benefits/
Submission: On November 15 via api from US — Scanned from DE
Form analysis 1 forms found in the DOM
POST https://share.msgapp.com/RESTPostForm.aspx
<form action="https://share.msgapp.com/RESTPostForm.aspx" method="POST">
<input type="hidden" name="Customer" value="ch000097073eArad">
<input type="hidden" name="cke" value="1">
<input type="hidden" name="ownerid" value="2">
<input type="hidden" name="overwrite" value="0">
<input type="hidden" name="DialogId" value="50">
<input type="hidden" name="PushExternal" value="1">
<input type="hidden" name="rurl" value="https://www.kedrab.com/ma-kedrab-benefits-thank-you/">
<div class="form-elements"><label for="FirstName">First Name: <span style="color:red">*</span></label><input id="FirstName" maxlength="40" name="FirstName" size="20" type="text"></div><br>
<div class="form-elements"><label for="LastName">Last Name: <span style="color:red">*</span></label><input id="LastName" maxlength="40" name="LastName" size="20" type="text"></div><br>
<div class="form-elements"><label for="Phone">Phone: <span style="color:red">*</span></label><input id="Phone" maxlength="40" name="Phone" size="20" type="text"></div><br>
<div class="form-elements"><label for="Email">Email: <span style="color:red">*</span></label><input id="Email" maxlength="40" name="Email" size="20" type="text"></div><br>
<div class="form-elements checkbox-wrap" style="width: 100%;"><label for="Representative_contact_request__c" class="label-for-check-box">Ask to receive a call from a Kedrion Biopharma representative for more information about KEDRAB and details on
how to order.</label><input id="Representative_contact_request__c" maxlength="40" name="Representative_contact_request__c" size="20" type="checkbox"></div><br>
<div class="google_captcha">
<div class="gglcptch gglcptch_v2">
<div id="gglcptch_recaptcha_340410658" class="gglcptch_recaptcha">
<div style="width: 304px; height: 78px;">
<div><iframe title="reCAPTCHA"
src="https://www.google.com/recaptcha/api2/anchor?ar=1&k=6LdNsS0UAAAAAPcJnjpHMjenG5pYIM4ulYIjz67o&co=aHR0cHM6Ly9rZWRyYWIuY29tOjQ0Mw..&hl=de&v=yZguKF1TiDm6F3yJWVhmOKQ9&theme=light&size=normal&cb=lkumwwchvt9e"
width="304" height="78" role="presentation" name="a-yjvxuknpdynn" frameborder="0" scrolling="no"
sandbox="allow-forms allow-popups allow-same-origin allow-scripts allow-top-navigation allow-modals allow-popups-to-escape-sandbox"></iframe></div><textarea id="g-recaptcha-response" name="g-recaptcha-response"
class="g-recaptcha-response" style="width: 250px; height: 40px; border: 1px solid rgb(193, 193, 193); margin: 10px 25px; padding: 0px; resize: none; display: none;"></textarea>
</div><iframe style="display: none;"></iframe>
</div>
<noscript>
<div style="width: 302px;">
<div style="width: 302px; height: 422px; position: relative;">
<div style="width: 302px; height: 422px; position: absolute;">
<iframe src="https://www.google.com/recaptcha/api/fallback?k=6LdNsS0UAAAAAPcJnjpHMjenG5pYIM4ulYIjz67o" frameborder="0" scrolling="no" style="width: 302px; height:422px; border-style: none;"></iframe>
</div>
</div>
<div style="border-style: none; bottom: 12px; left: 25px; margin: 0px; padding: 0px; right: 25px; background: #f9f9f9; border: 1px solid #c1c1c1; border-radius: 3px; height: 60px; width: 300px;">
<textarea id="g-recaptcha-response" name="g-recaptcha-response" class="g-recaptcha-response"
style="width: 250px !important; height: 40px !important; border: 1px solid #c1c1c1 !important; margin: 10px 25px !important; padding: 0px !important; resize: none !important;"></textarea>
</div>
</div>
</noscript>
</div>
</div><input type="submit" name="submit" value="SUBMIT">
<input name="formvalidationhunny" value="" style="display:none">
</form>Text Content
Intended for US Healthcare Professionals Only
Important Safety Information » | Full Prescribing Information »
Enroll
* ABOUT KEDRAB
* EFFICACY
* SAFETY
* MANUFACTURING
* DOSAGE AND ADMINISTRATION
* DOSE CALCULATOR
* HRIG ADMINISTRATION VIDEO
* STORAGE & HANDLING
* ORDERING AND REIMBURSEMENT
* ABOUT RABIES
* RABIES PREVALENCE
* POST-EXPOSURE PROPHYLAXIS
* PATIENT PROFILES
* RESOURCES
* RABIES PREVENTION SCENARIOS
* PRODUCT REPLACEMENT PROGRAM
* FORMULARY MONOGRAPH
* PRESS RELEASES
* PROFESSIONAL ORGANIZATIONS
* FAQs
* RABIES
* POST-EXPOSURE PROPHYLAXIS
* KEDRAB
* ABOUT KEDRAB
* EFFICACY
* SAFETY
* MANUFACTURING
* DOSAGE AND ADMINISTRATION
* DOSE CALCULATOR
* HRIG ADMINISTRATION VIDEO
* STORAGE & HANDLING
* ORDERING AND REIMBURSEMENT
* ABOUT RABIES
* RABIES PREVALENCE
* POST-EXPOSURE PROPHYLAXIS
* PATIENT PROFILES
* RESOURCES
* RABIES PREVENTION SCENARIOS
* PRODUCT REPLACEMENT PROGRAM
* FORMULARY MONOGRAPH
* PRESS RELEASES
* PROFESSIONAL ORGANIZATIONS
* FAQs
* RABIES
* POST-EXPOSURE PROPHYLAXIS
* KEDRAB
THE FIRST AND ONLY HRIG STUDIED IN CHILDREN1
Learn more about KEDRAB (Rabies Immune Globulin [Human]) – the only FDA-approved
human rabies immune globulin (HRIG) studied in children.1
Kedrion Biopharma is committed to rabies education, prevention, and clinical
excellence and maintains valuable relationships within the rabies prevention
community.
THE KEDRAB BROCHURE
Please complete the form below to receive your information.
Required *
First Name: *
Last Name: *
Phone: *
Email: *
Ask to receive a call from a Kedrion Biopharma representative for more
information about KEDRAB and details on how to order.
Terms and Conditions: Kedrion Biopharma Inc. (“Kedrion Biopharma”) respects the
privacy of your personal information. Kedrion Biopharma, and companies providing
services to Kedrion Biopharma, may use the information that you provide to send
you marketing or informational materials, analyze and use your information to
improve or develop services and programs, and contact you about marketing
programs or research about health topics that may be of interest to you.
Kedrion Biopharma, and companies providing services to Kedrion Biopharma, will
not sell or rent your personally identifiable information. For more information
regarding our Privacy Policy, click here.
Reference: 1. KEDRAB [package insert]. Fort Lee, NJ: Kedrion Biopharma Inc.;
2021.
Expand
INDICATIONS AND USAGE
KEDRAB is a human rabies immune globulin (HRIG) indicated for passive, transient
post-exposure prophylaxis (PEP) of rabies infection to persons of all ages when
given immediately after contact with a rabid or possibly rabid animal. KEDRAB
should be administered concurrently with a full course of rabies vaccine.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: None.
WARNINGS AND PRECAUTIONS:
Patients who can document previous complete rabies pre-exposure prophylaxis or
complete post-exposure prophylaxis should only receive a booster rabies vaccine
without KEDRAB because KEDRAB may interfere with the anamnestic response to the
rabies vaccine.
HYPERSENSITIVITY REACTIONS:
Hypersensitivity reactions, including anaphylaxis, may occur with KEDRAB. IgA
deficient patients with antibodies against IgA are at greater risk. Have
epinephrine available immediately to treat any acute severe hypersensitivity
reactions.
LIVE ATTENUATED VIRUS VACCINES:
KEDRAB administration may interfere with the development of an immune response
to live attenuated virus vaccines. If feasible, delay immunization with measles
vaccine for 4 months, and other live attenuated virus vaccines for 3 months,
after KEDRAB administration.
INTERFERENCE WITH SEROLOGICAL TESTING:
A transient rise of the various passively transferred antibodies in the
patient’s blood may result in misleading positive results of serologic tests
after KEDRAB administration.
Passive transmission of antibodies to erythrocyte antigens, e.g., A, B, and D,
may interfere with serologic tests for red cell antibodies such as the
antiglobulin test (Coombs’ test).
TRANSMISSIBLE INFECTIOUS AGENTS:
Because KEDRAB is made from human plasma donors hyper-immunized with rabies
vaccine, it may carry a risk of transmitting infectious agents, e.g., viruses,
the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the
Creutzfeldt-Jakob disease (CJD) agent. All infections suspected by a physician
possibly to have been transmitted by this product should be reported by the
physician or other healthcare provider to Kedrion Biopharma Inc. at
1-855-353-7466.
ADVERSE REACTIONS:
The most common adverse events in adult subjects treated with KEDRAB in clinical
trials were injection site pain, headache, muscle pain, and upper respiratory
tract infection.
In pediatric subjects treated with KEDRAB and a full course of rabies vaccine,
the most common adverse events were injection site pain, headache, fever, pain
in extremity, bruising (hematoma), fatigue and vomiting.
Less common adverse reactions (≤5%) in pediatric patients were injection site
redness (erythema), injection site swelling (edema), muscle pain, oral pain, and
wound complication. Insomnia was reported as a less common adverse reaction
(<5%) in pediatric patients occurring after 14 days of administration.
DRUG INTERACTIONS:
Patients who can document previous complete rabies pre-exposure prophylaxis or
complete post-exposure prophylaxis and have a confirmed adequate rabies antibody
titer should receive only a booster rabies vaccine (without KEDRAB) because
KEDRAB may interfere with the anamnestic response to the vaccine (ACIP).
KEDRAB can interfere with the immune response to the rabies vaccine. For this
reason, do not exceed the recommended KEDRAB dose or give additional (repeat)
doses of KEDRAB once rabies vaccination has been initiated.
KEDRAB can inactivate the rabies vaccine. For this reason, do not administer
KEDRAB in the same syringe as the rabies vaccine or near the anatomical site of
administration of the rabies vaccine.
To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at
1-855-353-7466 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Click here for full Prescribing Information.
KEDRION BIOPHARMA CUSTOMER SERVICE
Phone: 1-855-353-7466
Email: US_CustomerService@kedrion.com
Fax: 1-855-751-7951
RABIES UPDATES
If you are interested in receiving the most current information about KEDRAB,
proper PEP, and educational rabies resources, enroll now.
Enroll
ABOUT KEDRAB
Efficacy
Safety
Manufacturing
DOSAGE & ADMINISTRATION
Dose Calculator
HRIG Administration Video
Storage & Handling
ORDERING AND REIMBURSEMENT
ABOUT RABIES
Rabies Prevalence
Post-exposure Prophylaxis
Patient Profiles
RESOURCES
Rabies Prevention Scenarios
Product Replacement Program
Formulary Monograph
Press Releases
Professional Organizations
FAQS
Rabies
Post-exposure Prophylaxis
KEDRAB
Important Safety Information
Full Prescribing Information
Privacy Policy | Terms of Use | Contact | Sitemap | ©2021 Kedrion Biopharma Inc.
All Rights Reserved. June 2021
KR-0766-00-2020E
Expand
INDICATIONS AND USAGE
KEDRAB is a human rabies immune globulin (HRIG) indicated for passive, transient
post-exposure prophylaxis (PEP) of rabies infection to persons of all ages when
given immediately after contact with a rabid or possibly rabid animal. KEDRAB
should be administered concurrently with a full course of rabies vaccine.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: None.
WARNINGS AND PRECAUTIONS:
Patients who can document previous complete rabies pre-exposure prophylaxis or
complete post-exposure prophylaxis should only receive a booster rabies vaccine
without KEDRAB because KEDRAB may interfere with the anamnestic response to the
rabies vaccine.
HYPERSENSITIVITY REACTIONS:
Hypersensitivity reactions, including anaphylaxis, may occur with KEDRAB. IgA
deficient patients with antibodies against IgA are at greater risk. Have
epinephrine available immediately to treat any acute severe hypersensitivity
reactions.
LIVE ATTENUATED VIRUS VACCINES:
KEDRAB administration may interfere with the development of an immune response
to live attenuated virus vaccines. If feasible, delay immunization with measles
vaccine for 4 months, and other live attenuated virus vaccines for 3 months,
after KEDRAB administration.
INTERFERENCE WITH SEROLOGICAL TESTING:
A transient rise of the various passively transferred antibodies in the
patient’s blood may result in misleading positive results of serologic tests
after KEDRAB administration.
Passive transmission of antibodies to erythrocyte antigens, e.g., A, B, and D,
may interfere with serologic tests for red cell antibodies such as the
antiglobulin test (Coombs’ test).
TRANSMISSIBLE INFECTIOUS AGENTS:
Because KEDRAB is made from human plasma donors hyper-immunized with rabies
vaccine, it may carry a risk of transmitting infectious agents, e.g., viruses,
the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the
Creutzfeldt-Jakob disease (CJD) agent. All infections suspected by a physician
possibly to have been transmitted by this product should be reported by the
physician or other healthcare provider to Kedrion Biopharma Inc. at
1-855-353-7466.
ADVERSE REACTIONS:
The most common adverse events in adult subjects treated with KEDRAB in clinical
trials were injection site pain, headache, muscle pain, and upper respiratory
tract infection.
In pediatric subjects treated with KEDRAB and a full course of rabies vaccine,
the most common adverse events were injection site pain, headache, fever, pain
in extremity, bruising (hematoma), fatigue and vomiting.
Less common adverse reactions (≤5%) in pediatric patients were injection site
redness (erythema), injection site swelling (edema), muscle pain, oral pain, and
wound complication. Insomnia was reported as a less common adverse reaction
(<5%) in pediatric patients occurring after 14 days of administration.
DRUG INTERACTIONS:
Patients who can document previous complete rabies pre-exposure prophylaxis or
complete post-exposure prophylaxis and have a confirmed adequate rabies antibody
titer should receive only a booster rabies vaccine (without KEDRAB) because
KEDRAB may interfere with the anamnestic response to the vaccine (ACIP).
KEDRAB can interfere with the immune response to the rabies vaccine. For this
reason, do not exceed the recommended KEDRAB dose or give additional (repeat)
doses of KEDRAB once rabies vaccination has been initiated.
KEDRAB can inactivate the rabies vaccine. For this reason, do not administer
KEDRAB in the same syringe as the rabies vaccine or near the anatomical site of
administration of the rabies vaccine.
To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at
1-855-353-7466 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Click here for full Prescribing Information.
KEDRION BIOPHARMA CUSTOMER SERVICE
Phone: 1-855-353-7466
Email: US_CustomerService@kedrion.com
Fax: 1-855-751-7951
RABIES UPDATES
If you are interested in receiving the most current information about KEDRAB,
proper PEP, and educational rabies resources, enroll now.
Enroll
ABOUT KEDRAB
Efficacy
Safety
Manufacturing
DOSAGE & ADMINISTRATION
Dose Calculator
HRIG Administration Video
Storage & Handling
ORDERING AND REIMBURSEMENT
ABOUT RABIES
Rabies Prevalence
Post-exposure Prophylaxis
Patient Profiles
RESOURCES
Rabies Prevention Scenarios
Product Replacement Program
Formulary Monograph
Press Releases
Professional Organizations
FAQS
Rabies
Post-exposure Prophylaxis
KEDRAB
Important Safety Information
Full Prescribing Information
Privacy Policy | Terms of Use | Contact | Sitemap | ©2021 Kedrion Biopharma Inc.
All Rights Reserved. June 2021
KR-0766-00-2020E
Notifications